Evidence map›Paper›PMID 36157143›Full record

ReviewJournal of clinical and experimental hepatology

Alcohol and Acute-on-Chronic Liver Failure.

Maria Pilar Ballester, Richard Sittner, Rajiv Jalan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Serum HMGB1 and Alcohol-Related Liver Disease.Journal of clinical medicine · 2026
    Article
  3. Review
  4. Observational
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Alcohol-Associated Liver Disease - From Pathogenesis to Treatment.Journal of clinical and experimental hepatology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 3 countries.

Maria Pilar BallesterDigestive Disease Department, University Clinic Hospital of Valencia, Blasco Ibañez Av, 17, Valencia, 46010, Spain.
Richard SittnerDepartment of Hepatology and Gastroenterology, Campus Virchow-Klinikum, Charitéplatz 1 Berlin, 10117, Germany.
Rajiv JalanLiver Failure Group, Institute for Liver and Disease Health, University College London, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, United Kingdom.
Charité - Universitätsmedizin Berlin · DEEuropean Foundation for the Study of Chronic Liver Failure · ESHospital Clínico Universitario de Valencia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute-on-chronic liver failure (ACLF) is a clinical syndrome that occurs in patients with cirrhosis and is characterised by acute deterioration, organ failure and high short-term mortality. Alcohol is one of the leading causes of ACLF and the most frequently reported aetiology of underlying chronic liver disease. Among patients with alcoholic hepatitis (AH), ACLF is a frequent and severe complication. It is characterised by both immune dysfunction associated to an increased risk of infection and high-grade systemic inflammation that ultimately induce organ failure. Diagnosis and severity of ACLF determine AH prognosis, and therefore, ACLF prognostic scores should be used in severe AH with organ failure. Corticosteroids remain the first-line treatment for severe AH but they seem insufficient when ACLF is associated. Novel therapeutic targets to contain the excessive inflammatory response and reduce infection have been identified and are under investigation. With liver transplantation remaining one of the most effective therapies for severe AH and ACLF, adequate organ allocation represents a growing challenge. Hence, a clear understanding of the pathophysiology, clinical implications and management strategies of ACLF in AH is essential for hepatologists, which is narrated briefly in this review.

Indexed as

ACLF, Acute-on-chronic liver failureacute-on-chronic liver failureAH, alcoholic hepatitisalcoholic hepatitisALT, alanine aminotransferaseAPASL, Asian Pacific Association for the Study of the LiverAST, aspartate aminotransferasecirrhosisDAMPs, damage-associated molecular patternsEASL-CLIF, European Association for the Study of the Liver – Chronic Liver Failure ConsortiumGAHS, Glasgow alcoholic hepatitis scoreIL, interleukinINR, international normalised ratioMELD, model for end-stage liver diseaseNAC, N-acetylcysteineNACSELD, North American Consortium for the Study of End-Stage Liver DiseasePAMPs, pathogen-associated molecular patternsTNF, tumour necrosis factorWGO, World Gastroenterology Organization

Identifiers

PMID36157143
PMCPMC9499845
OpenAlexW4200376252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.